12:00 AM
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xifaxan rifaximin regulatory update

Salix disclosed in its 2Q11 earnings that an FDA advisory committee will meet in November to discuss an sNDA for Xifaxan rifaximin 550 mg tablets to treat irritable bowel syndrome (IBS). Salix said the committee will...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >